TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

83 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • Eczema / atopic dermatitis

    Molecular Signatures of Cutaneous Dupilumab Response

    Studying how dupilumab affects immune cells in eczema skin

    📍 University of California, San Francisco · San Francisco, CA · Get directions →

    This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Eczema / atopic dermatitis

    A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema

    Testing whether an experimental medicine is safe and works for eczema

    📍 Northridge Clinical Trials · Northridge, CA · +3 more US sites · Get directions →

    The purpose of this study is to learn if the study medicine (PF-08049820) is safe and effective for the treatment of atopic dermatitis (AD), also known as eczema, or atopic eczema. People with this condition may have severe itching and rashes on the skin.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • High blood pressureKidney disease

    📍 Research Site · Surprise, AZ · +17 more US sites · Get directions →

    International, Multicenter and Double-Blind study. The purpose is to measure the effect of baxdrostat in combination with dapagliflozin compared with baxdrostat/placebo on albuminuria, as well as safety, in participants with chronic kidney disease and high blood pressure.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Lupus (SLE)

    Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial

    Testing whether adding two lupus medicines to standard care improves kidney results

    📍 AARA Clinical Research · Glendale, AZ · +6 more US sites · Get directions →

    This is a Phase IV, open-label, randomized trial to determine whether the combination of Belimumab (BEL) and Voclosporin (VCS), plus background therapy with Mycophenolate Mofetil (MMF), improves the proportion of patients with proliferative lupus nephritis achieving complete renal response (CRR) compared to proportion of patients achieving CRR from recent clinical trials. This protocol will additionally determine whether combination therapy using Belimumab (BEL) and Voclosporin (VCS) facilitates rapid discontinuation of MMF.

    ✓ Study care freePhase 4Ages 18–80Learn more →
  • Lupus (SLE)

    📍 Investigative Site · Beverly Hills, CA · +9 more US sites · Get directions →

    The goal of this clinical trial is to learn if VENT-03 works to treat patients with cutaneous lupus erythematosus (CLE) who may or may not have systemic lupus erythematosus (SLE). Another goal is to learn about the safety of VENT-03 and how it is processed by the body.

    ✓ Study care freePhase 2Ages 18–80Learn more →
  • Eczema / atopic dermatitis

    Cardamom and Topical Roseomonas in Atopic Dermatitis

    Testing cardamom and a skin-applied germ to treat eczema

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: Atopic dermatitis (AD), also called eczema, is a chronic skin condition. AD can make skin dry and itchy, and sometimes it can lead to serious health problems, such as asthma, food allergies, eye infections, and sleep problems.

    ✓ Study care freePhase 2Ages 2–100Learn more →
  • Lupus (SLE)

    CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus

    Testing a cell therapy made from a person’s own immune cells for lupus

    📍 Children's Hospital of Philadelphia · Philadelphia, PA · Get directions →

    This is a single-center, single-arm, open-label phase 1/2 study of CART19 in children and young adults with refractory Systemic lupus erythematosus (SLE), including both patients diagnosed with lupus nephritis (LN) and patients with non-renal Systemic lupus erythematosus (SLE). Phase 1 will evaluate the safety of CART19 in 6-12 patients with Systemic lupus erythematosus (SLE).

    ✓ Study care freePhase 1Ages 12–29Learn more →
  • Lupus (SLE)

    Dapagliflozin in Active Lupus Nephritis

    Testing dapagliflozin for lupus-related kidney inflammation (kidney disease)

    📍 Massachusetts General Hospital · Boston, MA · +1 more US site · Get directions →

    Lupus nephritis is a chronic and life-threatening autoimmune cause of kidney disease that predominately impacts young people and can lead to kidney failure. Sodium-glucose co-transporter-2 inhibitors, including dapagliflozin, are known to improve outcomes for people with other causes of chronic kidney disease.

    ✓ Study care freePhase 4Ages 18–70Learn more →
  • Type 2 diabetesHigh blood pressure

    Polypill for Prevention of Cardiomyopathy

    Testing a pill combination to prevent heart muscle disease in people with type 2 diabetes and high

    📍 UT Southwestern Medical Center · Dallas, TX · Get directions →

    This study will investigate the utility of a polypill-based strategy for patients with type 2 diabetes mellitus and high risk of heart failure (HF), as assessed via the WATCH-DM risk score. Polypill therapy will consist of empagliflozin 12.5 mg, losartan 25, 50 or 100 mg, and finerenone 10 mg daily.

    ✓ Study care freePhase 1Ages 18–100Learn more →
  • Eczema / atopic dermatitis

    A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

    Testing the long-term safety and effects of a drug in people with eczema

    📍 Investigational Site · Fountain Valley, CA · +21 more US sites · Get directions →

    This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948). The LTE study will consist of 3 periods: 1) Screening Visit will coincide with the last visit of the Maintenance Period in the Parent Study 2) Extended Treatment Period 3) Post-treatment Follow-up Period.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Lupus (SLE)

    A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

    Testing whether different doses of BI 3000202 help adults with lupus

    📍 Wallace & Lee Center · Beverly Hills, CA · +29 more US sites · Get directions →

    This study is open to adults with systemic lupus erythematosus (SLE). The purpose of this study is to find out whether a medicine called BI 3000202 helps people with SLE.

    ✓ Study care freePhase 2Ages 18–74Learn more →
  • Eczema / atopic dermatitis

    Dupilumab De-escalation in Pediatric Atopic Dermatitis

    Testing whether stopping or lowering eczema treatment works for kids

    📍 Johns Hopkins Univerisity · Baltimore, MD · Get directions →

    This is a pilot investigator-blinded, randomized clinical trial to assess the feasibility of dupilumab treatment discontinuation or dose-reduction in children aged 1-17 years who have achieved sustained atopic dermatitis (AD) control on dupilumab.

    ✓ Study care freePhase 4Ages 1–17Learn more →
  • Obesity / overweightHigh blood pressure

    Impact GLP-1 Agonists Following Bariatric

    Testing whether GLP-1 medicines after bariatric surgery affect weight and blood sugar

    📍 University of Missouri Hospital · Columbia, MO · Get directions →

    Glucagon-like peptide 1 (GLP-1) is a hormone that helps regulate blood glucose levels through improved insulin sensitivity and release of insulin from the pancreas, control hunger, induce satiety and plays a role in the metabolic health of a person. GLP-1 receptor agonists (GLP1-RAs) have been shown to be effective in achieving weight loss in patients with type 2 diabetes while improving blood glucose control.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Eczema / atopic dermatitis

    A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

    Testing a medicine for moderate to severe eczema, compared with a placebo

    📍 Mountain West Derm - Blackhart PLLC dba Skin Cancer and Dermatology Institute · Phoenix, AZ · +39 more US sites · Get directions →

    This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Lupus (SLE)

    Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects with Discoid Lupus Erythematosus

    Testing a 1.5% ruxolitinib cream for discoid lupus in adults

    📍 INNO-6051 Site 03 · Fredericton, New Brunswick · Get directions →

    This study is a single-blind, intraindividual study to evaluate the efficacy of ruxolitinib 1.5 % cream in adult subjects with discoid lupus erythematosus.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Lupus (SLE)

    Trial of Belimumab in Early Lupus

    Testing belimumab in people with lupus diagnosed within 2 years

    📍 Feinstein Institute · Manhasset, NY · Get directions →

    This two year study will evaluate the effects of giving belimumab (Benlysta) to patients with Early Lupus. Early lupus is a diagnosis of lupus within 2 years.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Lupus (SLE)

    The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study

    Testing two ways of giving mycophenolate to children with lupus kidney disease

    📍 University of California, San Francisco · San Francisco, CA · +18 more US sites · Get directions →

    The study is a 1-year 2-part double-blinded placebo controlled 2-arm clinical trial. Treatment arms are (1) MMF dosed as per body-surface area (MMFBSA; 600mg/m2 body surface area per dose about every 12 hours) and (2) pharmacokinetically-guided precision-dosing of MMF (MMFPK; MMF dosed twice daily to achieve an area under the concentration-time curve (AUC0-12h) of MPA \>60-70 mg\*h/L.

    ✓ Study care freePhase 2Ages 8–20Learn more →
  • Lupus (SLE)

    RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

    Testing the safety and effects of CABA-201 in people with active lupus

    📍 University of California Irvine · Orange, CA · +20 more US sites · Get directions →

    RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Heart / cardiovascular disease

    Improving Coronary Vascular Health in Women

    Testing whether blood flow in heart arteries can be improved in women with HIV

    📍 Massachusetts General Hospital · Boston, MA · Get directions →

    Women with HIV have an increased risk of having a myocardial infarction (heart attack) as compared to women without HIV. One of the mechanisms underlying the increased risk of myocardial infarction among women with HIV may involve reduced ability to increase blood flow through large and small coronary arteries at times when increased flow of oxygen-carrying blood is needed.

    ✓ Study care freePhase 2Ages 45–75WomenLearn more →
  • Eczema / atopic dermatitis

    A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

    Testing different doses of a medicine versus placebo for eczema

    📍 Inmagene Site 1 · Lancaster, CA · +14 more US sites · Get directions →

    The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.

    ✓ Study care freePhase 2Ages 18–74Learn more →
  • Lupus (SLE)

    PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis

    Testing LUPKYNIS with other lupus medicines for kidney response in lupus nephritis

    📍 Purushotham & Akther Kotha MD, Inc. · La Mesa, CA · +14 more US sites · Get directions →

    The goal of this clinical study is to assess the efficacy and safety of LUPKYNIS® in combination with belimumab, obinutuzumab or anifrolumab at inducing rapid renal response in patients with lupus nephritis (LN).

    ✓ Study care freePhase 4Ages 18–75Learn more →
  • Eczema / atopic dermatitis

    Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD

    Testing how different doses of soquelitinib work for moderate to severe atopic dermatitis

    📍 Corvus Clinical Trials · South San Francisco, CA · Get directions →

    The main purpose of this study is to see how well different doses of soquelitinib work in participants with atopic dermatitis (AD) as compared to a placebo (pill with no medicine in it). To check this, the study doctors will examine participants' skin regularly to track how their AD changes during the study.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • High blood pressureCOPD (chronic lung disease)

    Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH

    Testing tadalafil to see if it improves shortness of breath in COPD with high blood pressure in the

    📍 Rocky Mountain Regional VA Medical Center, Aurora, CO · Aurora, CO · +4 more US sites · Get directions →

    The investigators will study whether the drug tadalafil improves shortness of breath in 126 Veterans with Chronic Obstructive Pulmonary Disease (COPD) and high blood pressure in the lungs. The investigators will also assess whether tadalafil improves quality of life, home daily physical activity, exercise endurance, the frequency of acute flares of COPD, blood pressure in the lungs, and lung function.

    ✓ Study care freePhase 2Ages 35–89Learn more →
  • Lupus (SLE)

    A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)

    Testing the safety and effects of belimumab in early lupus adults

    📍 GSK Investigational Site · Anniston, AL · +39 more US sites · Get directions →

    This is a prospective, open-label, single arm 3-year clinical study to describe the short-term and long-term efficacy and safety of belimumab in participants with autoantibody positive early SLE with ongoing disease activity despite stable first-line SLE therapy.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Lupus (SLE)

    A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

    Testing a CAR T cell treatment for adults with hard-to-treat lupus

    📍 Research Site · San Francisco, CA · +14 more US sites · Get directions →

    This is a Phase 1b/2, single-arm, open-label, multi-center, clinical study of AZD0120, a CD19/BCMA dual CAR T cell therapy, to evaluate the safety, tolerability, and efficacy in adult participants with refractory Systemic Lupus Erythematosus.

    ✓ Study care freePhase 1Ages 18–70Learn more →
  • Eczema / atopic dermatitis

    Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome

    Testing a daily medicine for eczema and hair loss in people with Down syndrome

    📍 Icahn School of Medicine at Mount Sinai · New York, NY · Get directions →

    This is a single-center, open-label, basket phase 2b trial that will enroll Down Syndrome (DS) participants with at least one inflammatory skin condition (Atopic Dermatitis (AD) and/or Alopecia Areata (AA)). Patients will receive Abrocitinib 100 mg daily for 12 weeks.

    ✓ Study care freePhase 2Ages 12+Learn more →
  • Eczema / atopic dermatitis

    A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

    Checking the long-term safety and effects of an eczema medicine in people who previously studied it

    📍 Hamilton Research, LLC · Alpharetta, GA · +2 more US sites · Get directions →

    This study will assess long-term safety and efficacy of Afimkibart (also known as RO7790121) in participants with Atopic Dermatitis (AD) who participated in previous afimkibart clinical trials.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Eczema / atopic dermatitis

    Lebrikizumab in Moderate-to-severe Atopic Dermatitis

    Testing a medicine called lebrikizumab for long-term improvement in eczema

    📍 Physioseq USA - CA · Folsom, CA · +1 more US site · Get directions →

    This research is studying a drug already approved for the treatment of atopic dermatitis (AD). This research collects health-related information and blood and skin samples to understand if the study drug, lebrikizumab, leads to long-term improvement in AD skin.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Lupus (SLE)

    📍 Loma Linda University health · Loma Linda, CA · +10 more US sites · Get directions →

    This phase II, randomized, double-blind, placebo-controlled study is designed to evaluate the safety, efficacy and pharmacokinetics (PK) of obinutuzumab in adolescent participants (AP) aged 12 to less than 18 with biopsy-confirmed proliferative lupus nephritis (LN). It will also evaluate open label safety and PK of obinutuzumab in pediatric participants (PP), aged 5 to \<12 with LN.

    ✓ Study care freePhase 2Ages 5–17Learn more →
  • Lupus (SLE)

    Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

    Testing the safety and best dose of an immune cell treatment with lupus drugs and chemotherapy

    📍 MD Anderson Cancer Center · Houston, TX · +1 more US site · Get directions →

    The goal of Safety Lead-In is to confirm the safety of tafasitamab when given to patients with SSc, SLE, and LN. The goal of Phase 1 is to find the recommended dose of AD-PluReceptor-NK cells in combination with tafasitamab and lymphodepleting chemotherapy that can be given to patients with the disease.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Eczema / atopic dermatitis

    Ethnic Differences in Mechanisms of Action of Dupilumab

    Studying how a common eczema treatment works differently by race

    📍 University of Michigan · Ann Arbor, MI · Get directions →

    Previous research has shown that Asian and African Americans are more likely to develop atopic dermatitis (AD) than their Caucasian counterparts. However, limited information is known about AD in Asian and African American populations because most molecular studies have focused on Caucasians with AD.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • High blood pressureDementia / Alzheimer's

    Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)

    Testing whether tightly lowering high blood pressure slows brain changes tied to Alzheimer’s

    📍 University of Texas Southwestern Medical Center · Dallas, TX · Get directions →

    The purpose of this study is to determine if intensive lowering of systolic blood pressure (SBP), using FDA approved medications (antihypertensive), reduces Alzheimer's Disease pathology (i.e., excessive brain amyloid and tau protein deposition) in older adults at high risk for memory decline or dementia.

    ✓ Study care freePhase 2Ages 60–85Learn more →
  • Heart / cardiovascular diseaseLupus (SLE)

    The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD

    Testing whether anifrolumab improves blood vessel risk markers in lupus

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: People with systemic lupus erythematosus (SLE) are at risk of developing complications in their blood vessels. This can increase the risk of heart attacks or stroke.

    ✓ Study care freePhase 2Ages 18–80Learn more →
  • Lupus (SLE)

    Safety of the Herpes Zoster Subunit Vaccine in Lupus

    Testing the safety of a shingles vaccine in people with lupus

    📍 NYU Langone Health · New York, NY · +1 more US site · Get directions →

    This randomized, double-blind, placebo-controlled, non-inferiority crossover study will evaluate the Herpes Zoster Sunbit (HZ/su) vaccine in SLE patients in order to evaluate safety and immunogenicity in patients with variable baseline clinical activities, ages and immunosuppressant exposures. The investigators hypothesize that HZ/su administration will be non-inferior to placebo with respect to the risk of moderate or severe SLE flare(s) occurring within 24 weeks of receiving the first dose of the assigned treatment.

    ✓ Study care freePhase 4Ages 18–90Learn more →
  • Lupus (SLE)

    A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)

    Testing a one-time cell treatment plus chemotherapy to treat severe lupus

    📍 University Of Alabama · Birmingham, AL · +18 more US sites · Get directions →

    The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) in patients with active, refractory systemic lupus erythematosus (SLE) or active, refractory lupus nephritis (LN).

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Lupus (SLE)

    Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)

    Testing a one-time cell therapy approach for severe lupus with kidney involvement

    📍 State University of New York Upstate Medical Center (SUNY) · Syracuse, NY · +1 more US site · Get directions →

    The purpose of this trial is to evaluate the efficacy and safety of obecabtagene autoleucel (obe-cel) administered once following lymphodepletion in participants with severe, refractory systemic lupus erythematosus (SLE) and active lupus nephritis (LN).

    ✓ Study care freePhase 2Ages 12–65Learn more →
  • Obesity / overweightHigh blood pressure

    Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease

    Testing treatments to lower high pressure in liver veins in people with advanced liver disease and

    💵 May compensate

    📍 Cleveland Clinic Main Campus · Cleveland, OH · Get directions →

    Cirrhosis is a form of advanced liver disease that can lead to serious complications, especially when combined with severe obesity. Many patients with cirrhosis also develop a condition called clinically significant portal hypertension (CSPH), which is increased pressure in the veins of the liver.

    ✓ Study care freePhase 4Ages 18–70Learn more →
  • Lupus (SLE)Rheumatoid arthritisCrohn's / ulcerative colitis (IBD)

    COVID-19 Booster and IIV Schedule in Immunocompromised Hosts

    Testing COVID-19 booster and flu vaccine schedules in people with lupus, rheumatoid arthritis, or

    📍 Maisonneuve -Rosemont Installation · Montreal, Quebec · Get directions →

    The goal of this pragmatic embedded open-label, 2 x 2 factorial phase II randomized controlled trial is to evaluate strategies to improve COVID-19 booster and influenza vaccine immunogenicity in people living with immunocompromising conditions (PLIC). The main questions it aims to answer are: 1.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Obesity / overweightHigh blood pressureCOPD (chronic lung disease)

    Feasibility of Semaglutide in Advanced Lung Disease

    Testing whether semaglutide can be given safely to people with advanced lung disease

    📍 University of Pennsylvania Perelman School of Medicine · Philadelphia, PA · Get directions →

    The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease. The main question\[s\] it aims to answer are: 1.

    ✓ Study care freePhase 1Ages 18–80Learn more →
  • Lupus (SLE)

    Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders

    Testing the safety and effects of Descartes-08 in young people with lupus

    📍 H01- Children's National Hospital · Washington D.C., DC · +1 more US site · Get directions →

    Safety, tolerability and efficacy of Descarte-08 in children, adolescents and young adults with childhood-onset systemic lupus erythematosus, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis

    ✓ Study care freePhase 1Ages 12+Learn more →
  • Lupus (SLE)

    A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

    Testing how mosunetuzumab works in people with lupus, with or without kidney disease

    📍 Clnica SER da Bahia · Salvador, Estado de Bahia · Get directions →

    This study will assess how mosunetuzumab works in people who have systemic lupus erythematosus (SLE) who may or may not also have active lupus nephritis (LN).

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Eczema / atopic dermatitis

    A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

    Testing how camoteskimab works in adults with moderate to severe eczema

    📍 AllerVie Clinical Research · Birmingham, AL · +32 more US sites · Get directions →

    This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.

    ✓ Study care freePhase 2Ages 18–65Learn more →
  • Eczema / atopic dermatitis

    📍 Physioseq, LLC /ID# 267266 · Sacramento, CA · +1 more US site · Get directions →

    Hidradenitis suppurativa (HS) and atopic dermatitis (AD) are chronic inflammatory skin diseases that lead to the development of skin lesions and symptoms such as pain and discomfort. The purpose of this study is to assess molecular changes in adult participants with moderate to severe HS or with moderate to severe AD.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Eczema / atopic dermatitis

    Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis

    Testing repeat under-the-skin doses of FB825 for adult eczema

    📍 First OC Dermatology · Fountain Valley, CA · +5 more US sites · Get directions →

    This is a randomized, placebo-controlled and double-blind study to evaluate the efficacy, pharmacokinetics, and Safety of repeat subcutaneous doses of FB825 in adults with moderate-to-severe atopic dermatitis.

    ✓ Study care freePhase 2Ages 18–65Learn more →
  • Lupus (SLE)

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Study Description: Systemic lupus erythematosus (SLE) occurs predominantly in women and is driven by type I interferon dysregulation and neutrophil hyperresponsiveness. Neutrophils in females have reduced mitochondrial bioenergetic capacity which affects immunometabolism.

    ✓ Study care freePhase 1Ages 18–120WomenLearn more →
  • Eczema / atopic dermatitis

    📍 ALS Global · Irving, TX · Get directions →

    This is a Phase 2, randomized, double-blind, vehicle-controlled clinical study evaluating the efficacy and safety of GX-03 topical ointment in adult subjects with moderate to severe atopic dermatitis (eczema). The study plans to enroll up to 120 eligible patients with a target of at least 100 completing the study and an ability to expand enrollment up to 200 subjects based on a pre-specified interim assessment conducted by an Independent Data Monitoring Committee (IDMC).

    ✓ Study care freePhase 2Ages 18–80Learn more →
  • Lupus (SLE)

    A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)

    Testing safety of an immune-cell treatment for people with lupus

    📍 Nkarta Investigational Site · Little Rock, AR · +16 more US sites · Get directions →

    This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with autoimmune diseases.

    ✓ Study care freePhase 1Ages 18–75Learn more →
  • High cholesterol

    A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia

    Testing how safe and well weekly injections of alirocumab work for high cholesterol in adults

    📍 Anaheim Clinical Trials · Anaheim, CA · +29 more US sites · Get directions →

    This study is researching an experimental drug called alirocumab, referred to as "study drug". In the United States, alirocumab is approved for the treatment of hypercholesterolemia (high blood cholesterol levels).

    ✓ Study care freePhase 2Ages 18–80Learn more →
  • Lupus (SLE)Rheumatoid arthritis

    A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

    Testing how safe inebilizumab and blinatumomab are in adults with lupus or rheumatoid arthritis

    📍 HonorHealth Research and Innovation Institute · Scottsdale, AZ · +16 more US sites · Get directions →

    The main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE) with nephritis (Subprotocol A) and to assess the safety and tolerability of subcutaneous (SC) blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part A) and in adult participants with active refractory rheumatoid arthritis (RA) (Subprotocol C Part A). The trial will also assess the efficacy of SC blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part B and Subprotocol C Part B).

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors

    Testing how BGE-102 affects inflammation blood tests and safety in people with obesity and heart

    📍 Site 108 · Chandler, AZ · +11 more US sites · Get directions →

    The purpose of this study is to learn about the effects of BGE-102 on blood biomarkers including hsCRP, which is a lab value used to measure inflammation. BGE-102 decreases inflammation which may improve obesity and cardiovascular health.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Lupus (SLE)

    Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users

    Tracking how anifrolumab passes into breast milk and affects infants in people with lupus

    📍 Research Site · Las Vegas, NV · Get directions →

    Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users (PRIMULA Lac) is a Post Marketing Requirements (PMR) study designed to fulfill the FDA post-marketing requirements. The study will collect data about the presence of anifrolumab in human breast milk and serum (maternal and infant) among lactating individuals who are receiving anifrolumab therapeutically via intravenous (IV) or subcutaneous (SC) administration and evaluate exposure and effects on the breastfed infant.

    ✓ Study care freePhase 4Ages 18–130WomenLearn more →
  • High blood pressureKidney disease

    Equol and Vascular Function in Women With Chronic Kidney Disease

    Testing whether equol affects blood vessel function in women with chronic kidney disease

    📍 University of Colorado Anschutz Medical Campus · Aurora, CO · Get directions →

    The risk of cardiovascular disease (CVD) is significantly elevated in patients with chronic kidney disease (CKD). Notably, women with CKD commonly experience menstrual disturbances induced by CKD, which may contribute to impaired vascular function and elevated CVD risk.

    ✓ Study care freePhase 2Ages 50+WomenLearn more →
  • Lupus (SLE)

    A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants

    Testing a new medicine in healthy adults and people with lupus

    📍 US06-0 · La Palma, CA · +5 more US sites · Get directions →

    A Phase 1/2a Study of DB-2304 in Healthy Participants and Participants with Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus

    ✓ Study care freePhase 1Ages 18–70Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    Mechanisms of Semaglutide Therapy in Heart Failure Patients

    Testing how semaglutide works in people with heart failure and obesity

    📍 Greenstone Biosciences · Palo Alto, CA · +1 more US site · Get directions →

    Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, primarily used for treatment of type-2 diabetes mellitus. GLP-1 receptors are present on pancreatic islet β-cells, δ-cells and α-cells.

    ✓ Study care freePhase 1Ages 20–80Learn more →
  • Lupus (SLE)

    A Study of Obexelimab in Patients With Systemic Lupus Erythematosus

    Testing obexelimab in people with lupus to study safety and effects

    📍 Sierra Pacific Arthritis and Rheumatology Centers · Fresno, CA · +15 more US sites · Get directions →

    This study aims to examine the efficacy and safety of obexelimab in participants with systemic lupus erythematosus (SLE).

    ✓ Study care freePhase 2Ages 18–70Learn more →
  • Lupus (SLE)

    Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases

    Testing high-dose treatment and a stem cell transplant for lupus

    📍 Children's Hospital of Philadelphia · Philadelphia, PA · Get directions →

    A subset of autoimmune diseases (ADs) in children and young adults are life-threatening and unresponsive to conventional treatments. In these patients, the delivery of high dose immunosuppressive therapy followed by autologous stem cell transplant (ASCT) offers a treatment strategy capable of purging the pathogenic, autoreactive immune system and an opportunity for "immune reset." This strategy has been used in adults across a myriad of indications with evidence for efficacy.

    ✓ Study care freePhase 2Ages 8–25Learn more →
  • Lupus (SLE)

    VIBRANT: VIB4920 for Active Lupus Nephritis

    Testing a treatment for active lupus nephritis alongside standard medicines

    📍 University of California San Diego School of Medicine: Division of Rheumatology, Allergy and Immunology · La Jolla, CA · +16 more US sites · Get directions →

    This is a multi-center double-blind placebo controlled clinical trial evaluating the efficacy of VIB4920 combined with mycophenolate mofetil (MMF) and prednisone in achieving a renal response in participants with active lupus nephritis (LN).

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Lupus (SLE)

    2-HOBA in Systemic Lupus Erythematosus

    Testing whether 2-HOBA changes blood pressure and immune activity in people with lupus

    📍 Vanderbilt University Medical Center · Nashville, TN · Get directions →

    This is a phase II randomized, placebo-controlled, double-blind, cross-over study to determine the effect of isolevuglandin (IsoLG) scavenging by 2-HOBA on blood pressure and immune activation in patients with SLE. 42 patients with stable SLE will be randomized to treatment sequence to receive placebo or 500mg 2-HOBA three times a day for 8 weeks followed by a 4 week washout and then 8 weeks of the other agent.

    ✓ Study care freePhase 2Ages 18+WomenLearn more →
  • Heart / cardiovascular disease

    Canagliflozin Targeting Vascular Inflammation

    Testing canagliflozin to reduce blood vessel inflammation in cardiovascular disease

    💵 May compensate

    📍 University of Ottawa Heart Institute · Ottawa, Ontario · Get directions →

    CANTOR SING is a pilot single center double blinded randomized study. The investigators will compare the effect of canagliflozin (300 mg daily - intervention arm) vs.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Heart / cardiovascular disease

    Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

    Testing a medicine to see its cardiovascular effects in adults on dialysis

    📍 Nephrology of North Alabama · Decatur, AL · +39 more US sites · Get directions →

    This is a two-part, phase 2b and phase 3 combined prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1: Phase 2b is a dose-finding study for CSL300 vs placebo.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Showing the first 60 of 83. Add filters or a location to narrow down.